Tenofovir for chronic hepatitis B virus infection in HIV-coinfected patients.
Tenofovir has significant activity against hepatitis B virus (HBV), but clinical data about its utility for treatment of hepatitis B in patients coinfected with HBV and HIV are limited. We report the long-term safety and efficacy of tenofovir in 6 HBV-HIV-coinfected persons who received tenofovir as part of their antiretroviral regimen and were followed up for an average of 26.8 months (range, 19 to 33 months). Four of 6 patients were positive for hepatitis B e antigen (HBeAg), and all 6 had initial HBV DNA levels greater than 7 log10 copies/mL. HBV DNA levels dropped by a mean (median) of 2.83 (3.40) and 3.92 (4.63) log10 after 12 and 24 months of treatment, respectively. After 24 months, 3 patients had HBV DNA levels below the limit of detection and 5 had HIV RNA levels below the limit of detection (less than 400 copies/mL). The sixth patient had stopped treatment and had a 0.14-log10 decrease in HIV RNA level at 36 months of follow-up. The CD4+ lymphocyte count increased by a mean (median) value of 47/microL (177/microL). No significant adverse events attributable to tenofovir therapy were reported.
Butt
Adeel A
AA
University of Pittsburgh School of Medicine, Division of Infectious Diseases, Center for Health Equity Research and Promotion, USA.
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006513:Hepatitis B e Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use*; D000068698:Tenofovir
D019380:Anti-HIV Agents; D006513:Hepatitis B e Antigens; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine